Celldex Therapeutics CLDX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $866K-88.5% | $1.55M-78.0% | $2.6M-73.9% | $5.79M-30.2% | $7.56M+24.5% | ||
| $265.46M+43.9% | $245.07M+49.8% | $216.68M+47.4% | $199.01M+46.0% | $184.5M+50.2% | ||
| $44.47M+10.4% | $43.84M+13.7% | $42.16M+13.6% | $41.53M+17.7% | $40.27M+20.6% | ||
| $309.93M+37.9% | $288.91M+43.0% | $258.84M+31.6% | $240.54M+30.7% | $224.77M+33.2% | ||
| -$309.06M-42.3% | -$287.37M-47.3% | -$256.24M-37.3% | -$234.75M-33.5% | -$217.21M-33.5% | ||
| -35,688.5%-32,815pp | -18,587.7%-15,809pp | -9,855.4%-7,984pp | -4,053.7%-1,936pp | -2,873.5%-194pp | ||
| -$283.65M-58.6% | -$258.76M-63.9% | -$224.53M-45.7% | -$199.61M-32.9% | -$178.85M-23.5% | ||
| -32,753.6%-30,388pp | -16,737.2%-14,488pp | -8,635.8%-7,091pp | -3,446.9%-1,637pp | -2,366.1%+19.9pp | ||
| -$4.27-58.1% | -$3.90-59.2% | -$3.38-31.0% | -$3.01-9.5% | -$2.70+5.6% | ||
| -$305.7M-42.9% | -$283.99M-48.0% | -$252.86M-37.8% | -$231.4M-34.0% | -$213.94M-34.0% | ||
| -35,299.7%-32,469pp | -18,369.1%-15,635pp | -9,725.3%-7,885pp | -3,995.9%-1,916pp | -2,830.3%-201pp | ||
| -$309.06M-42.3% | -$287.37M-47.3% | -$256.24M-37.3% | -$234.75M-33.5% | -$217.21M-33.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Celldex Therapeutics's revenue?
- Celldex Therapeutics (CLDX) generated $866.0K in revenue over the trailing twelve months, down 88.5% year over year.
- Is Celldex Therapeutics profitable?
- Celldex Therapeutics is not currently profitable: it reported a net loss of $283.6M over the trailing twelve months, a -32753.6% net margin.
- What is Celldex Therapeutics's earnings per share?
- Celldex Therapeutics's diluted EPS over the trailing twelve months is $-4.27.
- Where does Celldex Therapeutics's income statement data come from?
- Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
